menu
    • menu
    [{"orgOrder":0,"company":"Acelyrin","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"Izokibep","moa":"IL-17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.25,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ AyurMaya"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Affibody AB","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Affibody AB"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Series C Financing","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.29999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Access Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Access Biotechnology"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Not Applicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Not Applicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Not Applicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.62,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Morgan Stanley"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0.62,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.62,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Morgan Stanley"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Not Applicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lonigutamab","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Acelyrin \/ Not Applicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Not Applicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Izokibep","moa":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Not Applicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Izokibep","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Acelyrin

    Menu

    Acelyrin

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonigutamab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN Reports Positive Data for Lonigutamab in Thyroid Eye Disease

                            Details : VB-421 (lonigutamab) is a subcutaneously delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). It is being evaluated for thyroid eye disease.

                            Brand Name : VB-421

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 20, 2024

                            Lead Product(s) : Lonigutamab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN Announces Positive Results from Phase 2b/3 of Izokibep in Psoriatic Arthritis

                            Details : ABY-035 (izokibep) is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity. It is being evaluated for the treatment of psoriatic arthritis.

                            Brand Name : ABY 035

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 11, 2024

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051 and CX-801

                            Details : ABY-035 (izokibep) is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity. It is being evaluated for the treatment of hidradenitis suppurativa.

                            Brand Name : ABY 035

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 11, 2024

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program

                            Details : Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity. It is being evaluated in phase 2/3 clinical trials for the treatment of psoriatic arthritis (PsA).

                            Brand Name : ABY-035

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-S...

                            Details : IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A). It is designed to overcome monoclonal antibodies limitations for hidradenitis suppurativa indication. It is being investigated for moderate-to-severe Hidradenitis.

                            Brand Name : IMG-020

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 11, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $621.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Acelyrin, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option ...

                            Details : Company will use the proceeds to fund its operations, including the development of pipeline including Izokibep and commercialization activities, business development activities, and capital expenditures.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 09, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $621.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $540.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering

                            Details : The net proceeds will be used to advance the clinical development of izokibep through topline data in Phase 2b/3 trials of izokibep in each of HS, PsA, and uveitis.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $540.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Imp...

                            Details : IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A). It is designed to overcome monoclonal antibodies limitations for hidradenitis suppurativa indication. It is being investigated for psoriatic arthritis.

                            Brand Name : IMG-020

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 11, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa

                            Details : IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A), adinistered via subcutaneous injection. It is designed to overcome monoclonal antibodies limitations for Hidradenitis Suppurativa indication.

                            Brand Name : IMG-020

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Effi...

                            Details : Izokibep (IMG-020), is a unique interleukin- 17A inhibitor designed to overcome the limitations of monoclonal antibodies by utilizing high potency and small molecular size to enable high drug exposure levels through a single, subcutaneous injection.

                            Brand Name : IMG-020

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 09, 2022

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth